SPDR S&P Biotech ETF
672 hedge funds and large institutions have $9.23B invested in SPDR S&P Biotech ETF in 2025 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 176 increasing their positions, 269 reducing their positions, and 120 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
35% less repeat investments, than reductions
Existing positions increased: 176 | Existing positions reduced: 269
40% less first-time investments, than exits
New positions opened: 72 | Existing positions closed: 120
50% less call options, than puts
Call options by funds: $1.08B | Put options by funds: $2.17B
Holders
672
Holding in Top 10
15
Calls
$1.08B
Puts
$2.17B
Top Buyers
| 1 | +$294M | |
| 2 | +$287M | |
| 3 | +$269M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$191M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$85.2M |
Top Sellers
| 1 | -$167M | |
| 2 | -$145M | |
| 3 | -$138M | |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$111M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$61M |
